Tiziana Life Sciences (stock symbol: TLSA) Logo in transparent PNG and SVG formats

Tiziana Life Sciences Logo large

Tiziana Life Sciences Logo icon format

Tiziana Life Sciences Logo large for dark backgrounds

About Tiziana Life Sciences

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. The company was incorporated in 1998 and is headquatered in London, the United Kingdom.

  • Website domain: tizianalifesciences.com
  • Employees: 14
  • Marketcap: $64.94 Million USD

Page last updated on:

October 26th, 2021

Categories: